To ask the Scottish Executive whether the Scottish Medicines Consortium will adopt the same cost per quality adjusted life year threshold for cancer drugs as recently proposed by the National Institute for Health and Clinical Excellence (NICE).
The Scottish Medicines Consortium (SMC) is considering the implications for Scotland of the NICE methodology changes for appraising end of life drugs. However, the SMC already has the ability to exercise considerable flexibility.
The SMC assesses the cost per quality adjusted life year (QALY) of new drugs as part of its appraisal of health benefits. However, the SMC does not employ a rigid threshold in appraising drugs.
There is a two stage appraisal process. This involves a rapid assessment of the evidence by the New Drugs Committee (NDC) to provide a recommendation about the costs and benefits of using the medicine. This is followed by the SMC appraisal which looks again at the evidence together with the NDC advice, the case put forward by the patient interest groups and the company''s response to the NDC advice.
This approach ensures the SMC can consider all drugs flexibly, taking account of wider considerations as well as the economic evidence provided.